araag2/HINT huggingface dataset:
Clinical trial NCT00415363 (phase 2, status: completed)
Conditions: non small cell lung cancer, small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: enzastaurin, placebo
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Having radiologically proven brain metastases of lung cancer

          -  Having received whole brain radiotherapy with either 30 grays in 2 weeks or 20 grays
             in one week. Treatment with enzastaurin must start within 14 days after the last
             fraction of the whole brain radiotherapy

          -  No other previous radiotherapy to the brain except for radiosurgery at one occasion

          -  Adequate organ function as measured by appropriate laboratory tests.

          -  Age 18 years or older.

        Exclusion Criteria:

          -  Inability to swallow tablets or show conditions which could interfere with oral
             medication intake (e.g. vomiting, partial bowel obstruction).

          -  Inability to discontinue use of certain anti-epileptic drugs such as, carbamazepine,
             phenobarbital or phenytoin.

          -  Concurrent administration of warfarin

          -  Hemophilia

          -  Having had any systemic anti-cancer treatment within the last 2 weeks prior to
             enrolment.
Clinical trial NCT01397968 (phase 2, status: active, not recruiting)
Conditions: partial epilepsy
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: ykp3089, placebo
SMILES: NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of treatment resistant partial epilepsy;

          -  History of epilepsy for at least 2 years;

          -  Have at least 3 simple partial with motor component, complex partial or secondarily
             generalized seizures per month with no consecutive 21 day seizure free period.

          -  Currently treated on a stable dose of :

               -  1 - 3 AED's for at least 12 weeks prior to randomization.

               -  VNS will not be counted as AED; however the parameters must remain stable for at
                  least 4 weeks prior to baseline.

               -  Benzodiazepines taken at least once per week for epilepsy, or for anxiety or
                  sleep disorder, will be counted as 1 AED. Therefore only a maximum of two
                  additional approved AEDs will be allowed.

        Exclusion Criteria:

          1. A history of alcoholism, drug abuse, or drug addiction within the past 2 years.

          2. Subject has had status epilepticus within past 1 year.

          3. Subject has had greater than 2 allergic reactions to an AED or one serious
             hypersensitivity reaction to an AED.

          4. Subjects taking felbamate with less than 18 months continuous exposure.

          5. Subjects receiving phenytoin, phenobarbitone or metabolites of these drugs.

          6. No active suicidal plan/intent or active suicidal thoughts in the past 6 months.

          7. History of suicide attempt in the last 2 years; not more than 1 lifetime suicide
             attempt.

          8. Subject meets criteria for current major depressive episode (within 6 months).

          9. Use of intermittent rescue benzodiazepines more than once/month (1-2 doses in a
             24-hour period is considered one rescue) in the one month period prior to Visit 1.
Clinical trial NCT00367601 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib, bevacizumab
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological proof of non-small cell lung cancer meeting one of the following
             criteria:

               -  stage III b with a pleural effusion

               -  stage IV

          -  Histology must not be squamous cell.

          -  No prior chemotherapy or hormonal therapy.

          -  Prior radiation therapy must be completed at least 21 days prior to being registered
             for protocol therapy.

          -  No prior use of an epidermal growth factor receptor (EGFR) inhibitor or antiangiogenic
             agent.

          -  No treatment with any investigational agent within 30 days prior to being registered
             for protocol therapy.

          -  Measurable disease according to RECIST and obtained by imaging within 28 days prior to
             being registered for protocol therapy.

          -  ECOG Performance Status of 2 in the opinion of the treating investigator.

          -  Age > 18 years at the time of consent.

          -  Females of childbearing potential and males must be willing to use an effective method
             of contraception (hormonal or barrier method of birth control; abstinence) while on
             treatment and for a 6 week period thereafter.

          -  Females of childbearing potential must have a negative pregnancy test within 7 days
             prior to being registered for protocol therapy. Subjects are considered not of child
             bearing potential if they are surgically sterile (they have undergone a hysterectomy,
             bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.

          -  Females must not be breastfeeding.

          -  Able to comply with study and/or follow-up procedures.

        Exclusion Criteria:

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Evidence of central nervous system involvement or brain metastases confirmed by head
             CT or brain MRI within 28 days prior to being registered for protocol therapy.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to registration for protocol therapy.

          -  Anticipation of need for major surgical procedure during the course of the study.

          -  Minor surgical procedures such as fine needle aspirations or core biopsies within 7
             days prior to registration for protocol therapy.

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to registration for protocol therapy.

          -  Serious, non-healing wound, ulcer, or bone fracture.

          -  History of hemoptysis.

          -  Clinically significant infections as judged by the treating investigator.

          -  Other active malignancy
Clinical trial NCT00365794 (phase 2, status: completed)
Conditions: aging, obesity, insulin resistance, hypogonadism
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, Z16.11, Z16.21, D68.51, Z16.20, Z16.24, Z16.22, Z16.23
Drugs: topical testosterone gel 10 g/day
SMILES: CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Entry Criteria:

          -  Men > 60 years of age

          -  Total testosterone < 300 ng/dL

          -  Waist circumference >102 cm

          -  Fasting insulin level > 18 U/L

        Exclusion Criteria:

          -  PSA > 4.1, symptoms of obstructive uropathy (AUA score > 14), unexplained prostate
             nodule or gland firmness

          -  Hematocrit > 50%

          -  Malignancy other than cutaneous cancers

          -  Sleep apnea requiring CPAP

          -  History of myocardial infarction, angina or stroke within the previous 6 months

          -  Clinical diagnosis of diabetes or FPG > 126 mg/dL

          -  Hypothyroidism not controlled to euthyroid levels with medication for at least 3
             months

          -  LDL-C >160 mg/dL

          -  Transaminases > 1.5X ULN

          -  Systemic anticoagulation with warfarin

          -  Active progressive resistance training

          -  Dieting for weight loss

          -  Active inflammatory condition (e.g. rheumatoid arthritis)

          -  Use of any anabolic agent (e.g. growth hormone, testosterone precursor, anabolic
             steroid)or cytokine therapy in the proceeding 12 months
Clinical trial NCT01179269 (phase 2, status: withdrawn)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pazopanib plus paclitaxel
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    the study was stopped because the research team was unable to enroll any participants
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of Stage IIIB (with confirmed
             malignant pleural effusion) or Stage IV NSCLC.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  No prior systemic first-line therapy for Stage IIIB/IV NSCLC with chemotherapy or any
             other biologic therapy. Prior surgery and/or localized irradiation for NSCLC are
             permitted. Palliative radiation therapy must have ended 14 days prior to first dose of
             pazopanib. Subject with recurrence after previous NSCLC that has been treated with
             surgery with or without adjuvant chemotherapy/radiation for curative intent are
             eligible, provided 12 months have passed since this treatment ended.

        Exclusion Criteria:

          -  Appropriate for doublet therapy as first line therapy. At discretion of investigator.
Clinical trial NCT01184144 (phase 2/phase 3, status: withdrawn)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: pioglitazone
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Healthy woman age 18 - 45 years.

          2. Regular cycles (24-35 days).

          3. Pelvic pain ≥ 3 months.

          4. Negative pregnancy test.

          5. Non-lactating.

          6. No prior (<3 months) use of hormonal therapy.

          7. No history of liver disease.

          8. Suspected endometriosis and scheduled for surgery to confirm this diagnosis

          9. Surgery scheduled in follicular phase.

         10. Consent to participate in the study.

         11. Enrollment into data analysis portion of study if:

               -  Endometriosis diagnosed from surgical specimen by routine hematoxylin and eosin
                  staining and histological evaluation.

        Exclusion Criteria:

          1. Major psychiatric conditions or the abuse of alcohol or drugs which would make it
             difficult for the subject to complete study procedures.

          2. Active or prior infection with hepatitis, human immunodeficiency virus (HIV)
             infection, or history of high-risk activities (e.g., IV drug abuse) which would
             increase risk to laboratory personnel. Of note, no testing for hepatitis or HIV will
             be performed as part of this study and all tissues will be handled and discarded as if
             they were potentially infected.

          3. Patients with liver dysfunction (elevated liver enzymes > 2 times the upper limit of
             normal).

          4. Presence of pre-existing malignancy, including carcinoma of the breast or uterus.

          5. Women with other causes of chronic pelvic pain including infectious, gastrointestinal,
             musculoskeletal, neurologic or psychiatric.

          6. Elevated WBC.

          7. NYHA functional class I-IV heart failure.

          8. Diabetes mellitus.

          9. Known pregnancy or positive pregnancy test.
Clinical trial NCT00515099 (phase 2, status: terminated)
Conditions: new-onset type 1 diabetes mellitus
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: antithymocyte globulin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of type 1 diabetes (according to American Diabetes Association [ADA]
             criteria) within100 days of enrollment

          -  Positive for one or more autoantibodies (anti-glutamic acid decarboxylase [GAD],
             anti-insulin, or IA-2 autoantibodies)

          -  Peak stimulated C-peptide level >0.4 pmol/mL or >1.2ng/mL following an MMTT

          -  Serologic evidence of prior Epstein-Barr virus (EBV) infection (EBV seropositive)

          -  Willing to use acceptable forms of contraception

        Exclusion Criteria:

          -  Any sign of active infection (e.g., hepatitis, tuberculosis, EBV, cytomegalovirus
             (CMV), or toxoplasmosis) at screening

          -  Positive for human immunodeficiency virus (HIV), tuberculosis, or hepatitis B surface
             antigen (HBsAg) at screening

          -  Prior history of any significant cardiac disease, such as congestive heart failure,
             arrhythmia, or structural defects, or suspicion thereof

          -  Use of glucocorticoids in the 28 days prior to study entry; or topical use of
             glucocorticoids

          -  Use of diabetes medications (other than insulin) that may affect glucose homeostasis,
             such as metformin, sulfonylureas, thiazolidinediones, or amylin

          -  Evidence of liver dysfunction

          -  Evidence of kidney disease

          -  Pregnancy or plan to become pregnant

          -  Leukopenia (<3,000 leukocytes/µL), neutropenia (<1,500neutrophils/µL), lymphopenia
             (<800 lymphocytes/µL), or thrombocytopenia (<125,000 platelets/µL).

          -  Prior treatment with rabbit ATG or known hypersensitivity or exposure to rabbit
             sera-derived products

          -  Vaccination with a live virus within the last 6 weeks before enrollment

          -  Prior or current therapy that is known to cause a significant, ongoing change in the
             course of T1DM or immunologic status

          -  Any condition that may compromise study participation or may confound the
             interpretation of the study results
Clinical trial NCT00422604 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: salmeterol, tiotropium, gsk233705
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  females of non-childbearing potential or postmenopausal;

          -  history of COPD as defined by ATS/ERS criteria;

          -  moderate COPD responsive to ipratropium and salbutamol;

          -  current smoker or ex-smoker.

        Exclusion criteria:

          -  no instable COPD; max 1000 mcg inhaled steroids per day; no B-blockers
Clinical trial NCT00122434 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: bea 2180 br, tiotropium
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        1. Patients must have relatively stable, moderate to severe airway obstruction with an
             FEV1 >=30% and <= 60% of predicted normal and FEV1 <=70% of FVC at the baseline PFTs
             at Visit 1 (at both timepoints).

          2. All patients must have an increase in FEV1 of at least 12% from baseline (th e -10
             minute measurement) 45 min after inhalation of 80 ?g Atrovent MDI.

          3. Male or female patients 40 years of age or older.

          4. Smoker or ex-smoker with a history of more than 10 pack years.

        1. Patients with any other significant disease will be excluded. 2. Patients with a history
        of asthma or allergic rhinitis will be excluded.
Clinical trial NCT00335348 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib, dexamethasone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Patient was previously diagnosed with multiple myeloma based on standard criteria and
             currently requires second or *third line therapy because of PD, defined as a 25%
             increase in M-protein, or development of new or worsening of existing lytic bone
             lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium >11.5 mg/dL), or
             relapse from CR.*Patients will only be eligible for bortezomib as 3rd line therapy if
             they have received dexamethasone alone, thalidomide alone (or with corticosteroids) or
             revlimid alone (or with corticosteroids) as one of the 2 prior therapies.

          -  Patient is of a legally consenting age, as defined by local regulations.

          -  Patient is, in the investigator's opinion, willing and able to comply with the
             protocol requirements.

          -  Patient has given voluntary written informed consent before performance of any
             study-related procedure not part of normal medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to their future
             medical care.

          -  Female patient is either post-menopausal or surgically sterilized or willing to use an
             acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
             duration of the study.

          -  Male patient agrees to use an acceptable method for contraception for the duration of
             the study.

          -  Patient has measurable disease

          -  Patient has a Karnofsky performance status ≥60%.

          -  Patient has a life-expectancy >3 months.

        Exclusion Criteria:

          -  Primary Dexamethasone resistance

          -  Prior therapy with Bortezomib

          -  Prior severe allergic reactions to Bortezomib (Velcade), Boron or Mannitol

          -  Neuropathy > Grade 2 with pain by NCI-CTCAE criteria
Clinical trial NCT00143520 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: rivoglitazone, pioglitazone, placebo
SMILES: COC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes in male or female patients

          -  Between 18 and 75 years of age

          -  With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization

        Exclusion Criteria:

          -  Type 1 diabetics or type 2 diabetics currently on insulin therapy

          -  Patients unwilling or unable to discontinue their anti-diabetic medication(s)

          -  History of ketoacidosis

          -  History of therapy with rosiglitazone, troglitazone, pioglitazone
Clinical trial NCT00457951 (phase 2, status: terminated)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: open-label, placebo comparator: placebo-control arm 0.9% sodium chloride, odsh
SMILES: [Na+].[Cl-]
Reason stopped: 
    interim analysis: safety without efficacy odsh in patients with acute copd.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female patients (40 years of age or older) with an established diagnosis of
             COPD based upon medical history who are being admitted to the hospital to treat an
             exacerbation of COPD;

          2. Normal prothrombin time and activated partial thromboplastin time; Platelet count;
             hemoglobin and hematocrit

        Exclusion Criteria:

          1. Certain diseases such as:

               -  asthma;

               -  left heart failure or pulmonary embolism;

               -  lung cancer;

               -  pneumonia

               -  liver or kidney disease

               -  blood clotting disorder

               -  Positive HIV or hepatitis tests

               -  GI bleeding, physical trauma with bleeding, any disease with bleeding within 60
                  days of study entry

          2. Certain medications such as:

               -  Plavix®

               -  Warfarin

               -  Heparin therapy

               -  Certain antibiotics

          3. Exacerbations that are too severe (requiring intubation and mechanical ventilation)

          4. Women of child-bearing potential, pregnancy or breast-feeding

          5. Unable or unwilling to provide informed consent and follow study procedures.
Clinical trial NCT01504334 (phase 2, status: unknown status)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: pirfenidone, placebo
SMILES: CC1=CN(C(=O)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Written informed consent signed;

          2. 18-75 years of age;

          3. Clinically or multidisciplinarily diagnosed idiopathic pulmonary fibrosis(see 2011
             guidance );

          4. Resting state PaO2≥50mg, FVC%≥45% normal predicted value and DLCO≥30% normal predicted
             value.

        Exclusion Criteria:

          1. Allergic to pirfenidone;

          2. Dyspnea symptoms relieved in the past 6 months;

          3. Patients in acute exacerbation phase;

          4. Diabetic patients whose fasting venous glucose >11.1 mmol/L;

          5. Patients with malignant tumor and hemorrhagic diseases;

          6. Patients with serious underlying pulmonary disease;

          7. Patients with serious heart disease(NYHA class Ⅲ-Ⅳ), liver disease(ALT or AST 2 times
             above the upper level of normal value range), kidney disease(Cr above the upper level
             of normal value range);

          8. Patients who has taken Acetylcysteine in the past 3 months;

          9. Patients who has taken Prednisone>15mg/day(or other equivalent amount of
             glucocorticoid) and/or Immunosuppresants in the past 3 months;

         10. Patients who has taken interferon, penicillamine, colchine or other agents for the
             treatment of IPF;

         11. Pregnant or lactating women;

         12. Participated in other clinical trials in the past 1 month;

         13. The investigator assessed as inappropriate to participate in this clinical trial.